Anlon Healthcare Ltd., incorporated in 2013, is making headlines with its upcoming IPO. The company is a fast-growing player in the pharmaceutical manufacturing sector, specializing in pharma intermediates and active pharmaceutical ingredients (APIs). With a strong product pipeline, global approvals, and significant financial growth, the Anlon Healthcare IPO is expected to attract attention from retail and institutional investors alike.
Company Overview
Anlon Healthcare manufactures high-purity pharmaceutical intermediates and APIs that are used in formulations for medicines, nutraceuticals, personal care, and animal health products. Its products adhere to global pharmacopeia standards, including IP, BP, EP, JP, and USP.
The company also provides custom manufacturing solutions for complex chemicals, reducing impurities and achieving higher purity levels to meet global client requirements. Its quality-first approach is supported by four labs and a 34-member team, including 24 science graduates, ensuring rigorous testing and compliance.
Product Portfolio
Anlon Healthcare’s strength lies in its diverse product range, which includes:
-
Pharma Intermediates: Cyanoethylbenzoic acid, Ketonitrile, Methyldesloratadine, and more.
-
Active Pharmaceutical Ingredients (APIs): Used in formulations such as tablets, capsules, ointments, syrups, nutraceuticals, and veterinary products.
Currently, the company has 65 commercialized products, 28 in pilot stage, and 49 at laboratory scale. This scalable pipeline positions Anlon for continued growth.
Global Approvals and Competitive Strengths
Anlon has received Drug Master File (DMF) approvals from ANVISA, NMPA, and PMDA for APIs like loxoprofen sodium dihydrate and loxoprofen acid. It has already filed 21 DMFs globally and is expanding with filings for Ketoprofen and Dexketoprofen Trometamol.
Its competitive strengths include:
-
Strong product portfolio and scalable operations.
-
Experienced promoters and management team.
-
High entry barriers due to strict regulatory standards.
-
In-house testing and quality assurance.
-
Strong focus on quality, safety, and sustainability.
Financial Performance
The financials of Anlon Healthcare reflect robust growth. Between FY24 and FY25, revenue surged 81%, while profit after tax jumped 112%.
-
Total Income (FY25): ₹120.46 Cr
-
Profit After Tax (FY25): ₹20.52 Cr
-
EBITDA Margin: 26.88%
-
PAT Margin: 17.06%
With a market capitalization of ₹483.68 Cr, strong return ratios (ROE at 40.45%, ROCE at 21.93%), and a healthy debt/equity ratio of 0.73, the company stands out as financially sound.
Outlook
The Anlon Healthcare IPO presents investors with an opportunity to participate in India’s growing pharmaceutical sector. Backed by global approvals, strong financial performance, and a robust product pipeline, the company is well-positioned to capitalize on rising demand for high-quality APIs and intermediates worldwide.
